Recruiting

QOL Improvement

Sponsor:

Ottawa Heart Institute Research Corporation

Code:

NCT05136131

Conditions

Atrial Fibrillation

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Electrical cardioversion

Sham electrical cardioversion

Study Details

Brief summary:

Atrial fibrillation (AF) is a type of irregular heart rhythm due to electrical signal disturbances of the heart. It is a very common arrhythmia and the risk of developing AF increases with age and with other risk factors such as diabetes, high blood pressure, and underlying heart disease. The main complications of AF are heart failure and stroke. However, studies have shown that restoration of normal rhythm does not reduce these complications. Rather, these complications are mitigated by controlling the heart rate and using blood thinners to prevent stroke. Symptoms secondary to AF can occur due to the irregular heart rate and poor contraction in the atria, the top chambers of the heart. These symptoms include shortness of breath, fatigue, reduced exercise tolerance, and palpitations. Restoring sinus rhythm can sometimes alleviate these symptoms. Given that studies to date have not shown a difference in hard clinical endpoints between rate and rhythm control strategies, the decision to proceed with rhythm control depends on the patient symptom burden.

Rhythm control strategies in patients with persistent AF include cardioversion back to sinus rhythm with long-term recurrence prevention via anti-arrhythmic drugs (AADs) or catheter ablation. However, many studies of these procedures omit a sham placebo control arm. No atrial fibrillation procedural intervention has been compared to a sham procedure. The cardioversion procedure can easily be compared to a "sham" alternative, as it is non-invasive with an expected response within days-to-weeks. Thus, a cardioversion versus "sham" cardioversion trial will allow us to truly assess the impact of a rhythm-control strategy on QOL. It is hypothesized that cardioversion of atrial fibrillation leads to significant improvement in quality of life (QOL) compared to sham cardioversion.

Understanding the true QOL impact of sinus rhythm restoration in patients with persistent AF is of significant importance in guiding strategies for the management of AF. Hence, by evaluating what the true effect of cardioversion on QOL in this blinded study, we can better understand the role of medical management and AF ablation in our patients and assess resource allocation to these procedures.

Conditions

Atrial Fibrillation

Study ID

NCT05136131

Start date

Feb 10, 2023

Status verified date

Jun, 2026

Completion date

May, 2027

Anticipated

Primary completion date

May, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients age ≥ 18 years
  • Persistent atrial fibrillation
  • Unknown symptom burden related to AF

Exclusion Criteria:

  • Known left-atrial appendage thrombus
  • Prior catheter or surgical ablation for AF
  • Intolerance or contraindication to Amiodarone
  • Contraindication to appropriate anticoagulation
  • Patient is included in another randomized clinical trial
  • Patient is unable or unwilling to provide informed consent
  • Patient with a history of noncompliance with medical therapy
  • Patient does not meet all of the above listed inclusion criteria
  • Pregnancy (all women of child bearing age and potential will have a negative BHCG test before enrolment)
  • Breastfeeding
  • Patients for whom the investigator believes that the trial is not in the interest of the patient

Study Design

Enrollment

100 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: True cardioversion

Following anaesthesia administration, the unblinded team (non-MRP cardiologist / anesthesiologist will open the envelope indicating which arm the patient has been randomized to. Other members of the team will step out of the room. The unblinded non-MRP cardiologist will call out as per usual "All clear", following which a shock is delivered as per the Ottawa Cardioversion Protocol in the 'shock' arm.

sham comparator: Sham cardioversion

Following anaesthesia administration, the unblinded team (non-MRP cardiologist / anesthesiologist will open the envelope indicating which arm the patient has been randomized to. Other members of the team will step out of the room. No shock is delivered in the "sham" shock arm.

Interventions

Electrical cardioversion

Shocks are delivered as per the Ottawa Cardioversion Protocol in the "shock" arm. 1) 200J shock delivered using self-adhesive electrodes in an anteroposterior configuration. 2) 200J shock delivered using self-adhesive electrodes in an anterolateral configuration while applying pressure over the electrodes with disconnected standard handheld paddles. 3) 360J shock delivered using the same technique as in (2). 4) As per the treating physician's discretion.

Sham electrical cardioversion

No shock is delivered in the sham procedure arm.

Primary outcome measure

  • Difference between AFEQT Scores pre and post cardioversion [ Time Frame: 4 weeks ]

Central Contacts and Locations

Central contacts

Locations

Southlake Health

Recruiting

Newmarket, Ontario, Canada, L3Y 2P9

Contacts

Principal Investigator:

Mouhannad Sadek, MD

University of Ottawa Heart Institute

Recruiting

Ottawa, Ontario, Canada, K1Y 4W7

Contacts

More Information

Sponsor

Ottawa Heart Institute Research Corporation

Last update posted

Jul 1, 2026

Last verified

Jun, 2026

Keywords

  • Quality of life improvement
  • Electrical cardioversion
  • Sham cardioversion
  • Rhythm control
  • Placebo

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Ottawa Heart Institute Research Corporation on 2026-07-01.